leadf
logo-loader
RNS
viewDestiny Pharma PLC

Destiny Pharma PLC - Grant of Share Options

RNS Number : 5186M
Destiny Pharma PLC
21 January 2021
 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of share options

Brighton, United Kingdom - 21st January 2021 - Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following options ("Options") over a total of 180,436 ordinary shares of 1 pence in the Company have been granted under the Destiny Pharma plc 2020 Long Term Incentive Plan (the "Plan") to the following Directors and PDMRs in respect of bonuses due for the financial year ended 31 December 2020:

Name

Position

Total number of Options granted under award

Total Options held after the grant

Neil Clark

Chief Executive Officer

53,053

1,156,745

Shaun Claydon

Chief Financial Officer

39,230

700,768

William Love

Chief Scientific Officer

45,095

1,176,000

Jesus Gonzalez

Chief Medical Officer

43,058

492,242

 

The Options have been granted with a nominal exercise price and will vest on 21 January 2023.

 

Enquiries:

Destiny Pharma plc

+44 (0) 1273 704 440

Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)

 

finnCap Limited - Nominated Adviser and Joint Broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)

 

WG Partners LLP - Joint Broker

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig

 

Optimum Strategic Communications

+44 (0) 203 174 1789

Mary Clark / Shabnam Bashir / Manel Mateus

 

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

 

For further information, please visit https://www.destinypharma.com

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Neil Clark

2.               

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.

 

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.

c)

Price(s) and volume(s)

1 pence exercise price per Ordinary Share

 53,053 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

21 January 2021

f)

Place of the transaction

London Stock Exchange, AIM Market

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Shaun Claydon

2.               

Reason for the Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.

 

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.

c)

Price(s) and volume(s)

1 pence exercise price per Ordinary Share

39,230 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

21 January 2021

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bill Love

2.               

Reason for the Notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.

 

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.

c)

Price(s) and volume(s)

1 pence exercise price per Ordinary Share

45,095 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

21 January 2021

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jesus Gonzalez

2.               

Reason for the Notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.

 

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.

c)

Price(s) and volume(s)

1 pence exercise price per Ordinary Share

43,058 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

21 January 2021

f)

Place of the transaction

London Stock Exchange, AIM Market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUAONRARUAUAR

Quick facts: Destiny Pharma PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma presents at the Proactive One2One live investment forum

  Destiny Pharma's (LON:DES) Neil Clark (CEO) pitches to investors at the Proactive One2One live virtual forum. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its...

on 22/1/21

10 min read